New Board Members Join PolyTherics
News Aug 24, 2012
PolyTherics Limited has announced that Dr Anker Lundemose and Nigel Pitchford have joined its Board.
Dr Lundemose is co-founder of several companies including Symphogen A/S and Santaris A/S and was co-founder and CEO of Prosidion Ltd, a UK subsidiary of OSI Pharmaceuticals Inc. He is also a former managing director of OSI’s venture capital arm.
Dr Lundemose is medically qualified and has a PhD in molecular biology. He started his industry career in research with Novo Nordisk before moving into business development and has an international reputation in R&D productivity and for executing high profile licensing and M&A deals.
Nigel Pitchford is Managing Director of Healthcare Investments at Imperial Innovations Group plc. Nigel brings many years of experience as a venture capital investor to the PolyTherics board, drawn from his time with 3i and DFJ Esprit.
Ken Cunningham, Chairman of PolyTherics, welcomes Nigel and Anker to the board, saying, “As PolyTherics makes significant commercial progress with its expanded technology offering and its increasingly successful licensing strategy, these valuable additions to the Board set up the company for its next phase of development.”
Pathway in Neurons may Contribute to Neurodegenerative DiseaseNews
Pathway has received attention as potential drug target.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE